Excellence in Single Domain Biotherapeutics
Isogenica develops therapeutic VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
Our VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.
News & Events
Arvinas teams up with Isogenica using our CIS display technology to expand their PROTAC® platform
Announcing a new collaboration with Arvinas Isogenica is pleased to announce a technology license agreement with Arvinas, who will leverage...
PEGS 2022: Isogenica showcases plans for implementing machine learning tools
As part of our KTP partnership between Aston University and Nottingham University, we’re developing and integrating an ML-assisted pipeline for faster discovery and optimisation of VHH antibodies for next-generation biotherapeutics.
Stay up to date with our latest news and posts on LinkedIn
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.
Isogenica works with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents.
Isogenica’s LlamdA® VHH synthetic libraries are displayed in phage or in the company’s proprietary CIS Display technology.
These are combined to provide a powerful discovery engine for single domain biotherapeutics.
Careers at Isogenica
A career at Isogenica provides an opportunity to lead, execute or support the commercial development of next generation biotherapeutics.